Most Read

As part of this collaboration, Boehringer will utilise ExpressionEdits’ AI-powered platform, Genetic Syntax Engine, designed to boost gene expression without altering the genetic sequence, for the development of

Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and

The partnership will utilise the Pb-212 production technology and radionuclide development infrastructure of AdvanCell alongside Lilly’s expertise in drug development and drug candidate programmes. It will support the

In March last year, Fennec Pharmaceuticals entered an exclusive licensing agreement, granting Norgine commercialisation rights for the injection in Australia, New Zealand, and Europe. Under this agreement, Fennec

This expansion includes exclusive distribution agreements as well as new market authorisation transfers. The current agreement in Japan follows the last year agreement between the two companies for

The collaboration brings together LEO Pharma’s “expertise” in medical dermatology and DEBRA Research’s pharmaceutical experience to develop novel medicines for this condition. DEBRA Research managing director Prof Hubert Truebel

Concurrently, the company also secured a funding of $27m in Series B round. The proceeds are set to be utilised for progressing the therapy through a Phase I

The acquisition primarily comprises cash payments, with a smaller portion in the form of BioNTech American Depositary Shares. In addition, there are potential performance-based payments of up to

The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year,